Jiya Sun

Assessment of TMB, PD-L1, and lymphocyte to monocyte ratio as predictive potential in a phase Ib study of sintilimab in patients with advanced solid tumors.

B. Peng, L. Teng, N. Xu, 2021, American journal of cancer research.

Tiaolipiwei Acupuncture Reduces Albuminuria by Alleviating Podocyte Lesions in a Rat Model of Diabetic Nephropathy

Xinju Li, Jiya Sun, Zhilong Zhang, 2018, Evidence-based complementary and alternative medicine : eCAM.

Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)

X. Chen, N. Xu, Yunpeng Liu, 2021, Nature communications.

Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Non-squamous NSCLC in the Phase III ORIENT-11 Study.

Baolan Li, Wei-min Li, B. Peng, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)

Yang Zhang, Changli Wang, Wen-Wei Hu, 2022, Cancer communications.

Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody

Junjian Liu, Ya-Wei Xiong, B. Prinz, 2021, Cancer Immunology, Immunotherapy.

Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity

M. Zhang, Zhihai Wu, Bingliang Chen, 2021, Nature Communications.

Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)

X. Chen, Wei Li, Y. Shu, 2022, Nature Communications.

Efficacy and safety of fire-needle in the treatment of gouty arthritis

Shenjun Wang, Yihua Fan, R. Jin, 2020, Medicine.

Classification of Tumor Immune Microenvironment (TIME) According to PD-L1 Expression and Immune Infiltration Predicts Response to Immunotherapy plus Chemotherapy in Advanced NSCLC Patients.

Huaqiang Zhou, W. Fang, Yu-xiang Ma, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells

Yaning Li, Min Wu, Zhihai Wu, 2023, Nature Cancer.